Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Gilead Sciences, Inc.

Capitalization 184B 158B 143B 137B 250B 16,939B 258B 1,686B 675B 8,121B 692B 677B 29,077B P/E ratio 2026 *
20.6x
P/E ratio 2027 * 17.8x
Enterprise value 189B 162B 147B 140B 257B 17,363B 265B 1,728B 692B 8,324B 709B 694B 29,804B EV / Sales 2026 *
6.26x
EV / Sales 2027 * 5.66x
Free-Float
99.9%
Yield 2026 *
2.19%
Yield 2027 * 2.43%
1 day+1.32%
1 week+0.49%
Current month-0.26%
1 month+0.90%
3 months+22.43%
6 months+28.90%
Current year+21.04%
1 week 142.77
Extreme 142.77
149.38
1 month 142.77
Extreme 142.77
156.95
Current year 116.88
Extreme 116.88
157.29
1 year 93.37
Extreme 93.37
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 60 01/03/2019
Director of Finance/CFO 56 01/11/2019
Chief Tech/Sci/R&D Officer 64 02/01/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5d. change 1-year change 3-years change Capi.($)
+1.32%+0.49%+26.75%+86.87% 184B
-0.70%-0.63%+20.68%+217.87% 895B
+0.46%-1.23%+45.32%+60.75% 587B
-0.19%-2.93%+4.78%+51.63% 401B
-1.67%-8.64%+10.56%+24.05% 345B
-0.64%-5.37%+26.25%+61.70% 300B
-0.98%-4.16%+25.96%+35.32% 306B
-0.02%-2.29%+22.95%+8.73% 289B
-0.41%-0.42%+14.68%+64.76% 202B
+0.44%+0.90%-53.32%-49.66% 171B
Average -0.24%-1.14%+14.46%+56.20% 368.14B
Weighted average by Cap. -0.34%-1.51%+19.54%+84.77%

Financials

2026 *2027 *
Net sales 30.19B 25.92B 23.43B 22.44B 40.98B 2,773B 42.27B 276B 111B 1,329B 113B 111B 4,759B 32.05B 27.52B 24.87B 23.82B 43.5B 2,943B 44.87B 293B 117B 1,411B 120B 118B 5,052B
Net income 8.98B 7.71B 6.97B 6.67B 12.19B 825B 12.57B 82.08B 32.87B 395B 33.7B 32.98B 1,416B 9.91B 8.51B 7.69B 7.37B 13.45B 910B 13.88B 90.61B 36.28B 436B 37.2B 36.41B 1,563B
Net Debt 4.61B 3.96B 3.58B 3.43B 6.26B 423B 6.46B 42.15B 16.88B 203B 17.3B 16.94B 727B -3.1B -2.66B -2.41B -2.3B -4.21B -285B -4.34B -28.33B -11.35B -136B -11.63B -11.38B -489B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).
Employees
17,000
Date Price Change Volume
10/03/26 148.56 $ +1.32% 5,098,461
09/03/26 146.63 $ +1.88% 5,210,502
06/03/26 143.93 $ -0.83% 4,921,313
05/03/26 145.14 $ -2.08% 6,944,156
04/03/26 148.22 $ +0.26% 6,925,216
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
148.56USD
Average target price
156.59USD
Spread / Average Target
+5.41%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW